TP53 and cancer: Mutations in p53 are associated with BC sensitivity to clinical MTAs [31, 32], whereas clinical responses of BC to chemotherapy have no direct relationship to the classical p53-dependent apoptosis, a pattern also observed in other cancer cell models [33].